https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45164 Wed 26 Oct 2022 14:11:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50458 Wed 26 Jul 2023 13:35:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34918 Wed 24 Nov 2021 15:53:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43392 Wed 22 Mar 2023 15:32:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27984 Wed 15 Dec 2021 16:06:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47145 Wed 14 Dec 2022 15:27:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51667 2) based on acute neuroimaging data in a Bayesian hierarchical framework. Lesions encompassing bilateral subcortical nuclei and left-lateralized regions in proximity to the insula explained outcomes across men and women (area under the curve = 0.81). A pattern of left-hemispheric posterior circulation brain regions, combining left hippocampus, precuneus, fusiform and lingual gyrus, occipital pole and latero-occipital cortex, showed a substantially higher relevance in explaining functional outcomes in women compared to men [mean difference of Bayesian posterior distributions (men – women) = −0.295 (90% highest posterior density interval = −0.556 to −0.068)]. Once validated in prospective studies, our findings may motivate a sex-specific approach to clinical stroke management and hold the promise of enhancing outcomes on a population level.]]> Wed 13 Sep 2023 10:08:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14299 Wed 11 Apr 2018 17:07:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6849 Wed 11 Apr 2018 16:39:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12270 Wed 11 Apr 2018 15:59:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10738 Wed 11 Apr 2018 15:45:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26195 Wed 11 Apr 2018 15:00:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14317 Wed 11 Apr 2018 14:17:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31227 Wed 11 Apr 2018 14:09:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2014 65%, > 125 participants per gender group, and age and gender separation of results (stratification). Results: There were significant differences in the definitions used, the time frames of interest, and the populations surveyed. There was significant heterogeneity across studies. Overall prevalence of urinary incontinence for Australian adults was estimated to be 19.3% and 2.2% in Australian women and men, respectively. Overall prevalence of faecal incontinence was estimated to be 5.3% and 5.5% in Australian women and men, respectively. Conclusions: It is disappointing that with so many studies published in this area, there is still a lack of high quality, basic descriptive epidemiology of this important health problem. These estimates of the prevalences of urinary and faecal incontinence should assist policy making in this area.]]> Wed 11 Apr 2018 11:43:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13533 21 on the Kessler 10) were examined using logistic regression. Results: Not being in a married or defacto relationship (OR 0.69; 99% CI 0.51-0.94), lower education (OR 0.52; 99% CI 0.38-0.71) and decreased social support (OR 0.36; 99% CI 0.31-0.42) significantly predicted psychological distress. There was a significant interaction of age and remoteness (OR 0.84; 99% CI 0.67-1.00), indicating that as remoteness increases, older persons are less likely to be highly distressed, as well as a significant interaction of social support and remoteness (OR 1.22; 99% CI 1.04-1.44), indicating that as remoteness decreases, persons with low levels of social support are more likely to be highly distressed. Conclusions: Remoteness may moderate the influence of social support and age on psychological distress outcomes.]]> Wed 11 Apr 2018 11:23:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20989 Wed 11 Apr 2018 11:20:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4378 A, causes overexpression and supports uncontrollable cellular growth. This polymorphism has been associated with an increased risk of developing many cancers, including endometrial cancer. Methods: The 870 G>A polymorphisms (rs605965) in the cyclin D1 gene was genotyped in an Australian endometrial cancer case-control population including 191 cases and 291 controls using real-time PCR analysis. Genotype analysis was performed using chi-squared (χ²) statistics and odds ratios were calculated using unconditional logistic regression, adjusting for potential endometrial cancer risk factors. Results: Women homozygous for the variant cyclin D1 870 AA genotype showed a trend for an increased risk of developing endometrial cancer compared to those with the wild-type GG genotype, however this result was not statistically significant (OR 1.692 95% CI (0.939-3.049), p = 0.080). Moreover, the 870 G>A polymorphism was significantly associated with family history of colorectal cancer. Endometrial cancer patients with the homozygous variant AA genotype had a higher frequency of family members with colorectal cancer in comparison to endometrial cancer patients with the GG and combination of GG and GA genotypes (GG versus AA; OR 2.951, 95% CI (1.026-8.491), p = 0.045, and GG+GA versus AA; OR 2.265, 95% CI (1.048-4.894), p = 0.038, respectively). Conclusion: These results suggest that the cyclin D1 870 G>A polymorphism is possibly involved in the development of endometrial cancer. A more complex relationship was observed between this polymorphism and familial colorectal cancer.]]> Wed 11 Apr 2018 10:44:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14022 Wed 11 Apr 2018 10:41:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9714 Wed 11 Apr 2018 09:43:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15464 Wed 10 Jul 2019 15:19:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34942 Wed 09 Feb 2022 15:56:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50848 Wed 09 Aug 2023 09:31:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52396 Wed 06 Mar 2024 15:53:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32816 Wed 02 Mar 2022 14:28:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53479 Tue 28 Nov 2023 16:00:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54542 Tue 27 Feb 2024 20:40:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54485 Tue 27 Feb 2024 15:11:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51991 Tue 26 Sep 2023 11:00:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31265 Tue 24 Jul 2018 09:52:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47648 Tue 24 Jan 2023 14:51:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43840 Tue 21 Mar 2023 17:30:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47256 Tue 17 Jan 2023 12:30:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41920 0.7. Despite defined cut-off values, no jurisdiction prescribes a reference equation for use; multiple equations exist. We hypothesized that access to subsidized treatment varies depending on the chosen equation. The %FVC and %TLco from different commonly used reference equations across general respiratory patients, and IPF-specific patients, were compared. Methods: FVC and TLco measurements from a large general respiratory laboratory and the Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR) database were analysed using multiple equations. Differences between %FVC and %TLco for each equation were calculated, with particular interest in classification of patients (%) at the threshold for subsidized treatment. Results: A total of 20 378 general respiratory database results were analysed. The %FVC ≥ 50% increased from 86% with the Roca equation to 96% with Quanjer (European Coal and Steal Community, ECSC) and %TLco≥30% increased from 91% with Paoletti to 98% with Thompson. However, overall increase in eligibility for subsidized treatment was modest, varying from 48.2% to 49.2%. A total of 545 AIPFR database results were analysed. The %FVC ≥ 50% increased from 73% with Roca to 94% with Quanjer (ECSC) and %TLco≥30% increased from 87% with Paoletti to 96% with Miller. Overall eligibility for subsidized treatment in the AIPFR group varied from 73.6% to 82.8% between surveyed interstitial lung disease (ILD) centres based entirely on the equation used. Conclusion: Substantial variability exists between reference equations, impacting access to subsidized treatment. Treating clinicians should be aware of this when assessing patients around public funding thresholds.]]> Tue 16 Aug 2022 11:07:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46889 Tue 06 Dec 2022 11:20:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51452 2) were modeled within purpose-built Bayesian linear and logistic regression frameworks. Interaction effects between stroke lesions and a high vs low WMH burden were integrated via hierarchical model structures. Models were adjusted for age, age2, sex, total DWI lesion and WMH volumes, and comorbidities. Data were split into derivation and validation cohorts. Results: A total of 928 patients with AIS contributed to acute stroke severity analyses (age: 64.8 [14.5] years, 40% women) and 698 patients to long-term functional outcome analyses (age: 65.9 [14.7] years, 41% women). Stroke severity was mainly explained by lesions focused on bilateral subcortical and left hemispherically pronounced cortical regions across patients with both a high and low WMH burden. Lesions centered on left-hemispheric insular, opercular, and inferior frontal regions and lesions affecting right-hemispheric temporoparietal regions had more pronounced effects on stroke severity in case of high compared with low WMH burden. Unfavorable outcomes were predominantly explained by lesions in bilateral subcortical regions. In difference to the lesion location–specific WMH effects on stroke severity, higher WMH burden increased the odds of unfavorable outcomes independent of lesion location. Discussion: Higher WMH burden may be associated with an increased stroke severity in case of stroke lesions involving left-hemispheric insular, opercular, and inferior frontal regions (potentially linked to language functions) and right-hemispheric temporoparietal regions (potentially linked to attention). Our findings suggest that patients with specific constellations of WMH burden and lesion locations may have greater benefits from acute recanalization treatments. Future clinical studies are warranted to systematically assess this assumption and guide more tailored treatment decisions.]]> Tue 05 Sep 2023 18:01:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32708 Tue 05 Mar 2024 15:32:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43825 Tue 04 Oct 2022 11:04:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35092 Tue 01 Nov 2022 11:14:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35011 Thu 30 May 2019 15:05:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52122  2) was modeled in a Bayesian logistic regression framework. Effects of individual brain regions were captured as two compound effects for (i) six bilateral rich club and (ii) all further non-rich club regions. In spatial specificity analyses, we randomized the split into "rich club" and "non-rich club" regions and compared the effect of the actual rich club regions to the distribution of effects from 1000 combinations of six random regions. In sex-specific analyses, we introduced an additional hierarchical level in our model structure to compare male and female-specific rich club effects. A total of 822 patients (age: 64.7[15.0], 39% women) were analyzed. Rich club regions had substantial relevance in explaining unfavorable functional outcome (mean of posterior distribution: 0.08, area under the curve: 0.8). In particular, the rich club-combination had a higher relevance than 98.4% of random constellations. Rich club regions were substantially more important in explaining long-term outcome in women than in men. All in all, lesions in rich club regions were associated with increased odds of unfavorable outcome. These effects were spatially specific and more pronounced in women.]]> Thu 28 Sep 2023 15:03:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26531 Thu 28 Oct 2021 12:37:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30240 EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a genome-wide search for tandem repeats, we found that EIG121 contains a short tandem repeat (STR) in its upstream regulatory region which has the potential to alter gene expression. The presence of this STR has not previously been analysed in relation to breast or endometrial cancer risk. Results: In this study, the lengths of this STR were determined by PCR, fragment analysis and sequencing using DNA from 223 breast cancer patients, 204 endometrial cancer patients and 220 healthy controls to determine if they were associated with the risk of developing breast or endometrial cancer. We found this repeat to be highly variable with the number of copies of the AG motif ranging from 27 to 72 and having a bimodal distribution. No statistically significant association was identified between the length of this STR and the risk of developing breast or endometrial cancer or age at diagnosis. Conclusions: The STR in the upstream regulatory region of EIG121 is highly polymorphic, but is not associated with the risk of developing breast or endometrial cancer in the cohorts analysed here. While this polymorphic STR in the regulatory region of EIG121 appears to have no impact on the risk of developing breast or endometrial cancer, its association with disease recurrence or overall survival remains to be determined.]]> Thu 28 Oct 2021 12:35:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37635 65% by area and 16/50 a low grade stenosis of between 40-65% by area compared to 1/50 low grade stenoses in this segment in the controls. The commonest cause of the stenosis was a giant arachnoid granulation. The optic nerve sheaths were larger in MS than controls (p=0.0006). Comparing MS patients with transverse sinus stenosis to those without, the pituitary height was 16% smaller and BMI 25% larger (p=0.02 and 0.003 respectively) Conclusion: In patients with MS, the reduction in venous sinus compliance is associated with venous outflow stenoses in the transverse sinuses which increases the upstream venous pressure and dilates the sagittal sinuses. This finding suggests a continuum exists between MS and idiopathic intracranial hypertension.]]> Thu 24 Mar 2022 11:30:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48040 Thu 23 Mar 2023 10:12:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54905 Thu 21 Mar 2024 11:56:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25845 Thu 17 Mar 2022 14:40:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48407 Thu 16 Mar 2023 14:03:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32703 Thu 12 Jul 2018 11:51:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50897 Thu 10 Aug 2023 12:35:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35783 Thu 04 Nov 2021 10:38:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33106 0.05). Conclusions: Stroke survivors with nonresolving fatigue reported reduced fatigue and improved quality of life after taking 200 mg daily treatment with modafinil.]]> Thu 03 Feb 2022 12:21:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7393 Sat 24 Mar 2018 08:42:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8376 30, and with a history of arthritis but no significant association with other demographic variables. Conclusion: Pedometry is feasible in an elderly sample, and research involving pedometers must take days of the week into account.]]> Sat 24 Mar 2018 08:39:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7492 Sat 24 Mar 2018 08:37:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7490 Sat 24 Mar 2018 08:37:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7491 Sat 24 Mar 2018 08:37:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9354 Sat 24 Mar 2018 08:36:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9346 Sat 24 Mar 2018 08:36:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1671 Sat 24 Mar 2018 08:30:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1709 Sat 24 Mar 2018 08:27:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12564 Sat 24 Mar 2018 08:18:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13231 Sat 24 Mar 2018 08:17:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13263 Sat 24 Mar 2018 08:15:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10940 Sat 24 Mar 2018 08:10:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18172 Sat 24 Mar 2018 08:04:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21473 Sat 24 Mar 2018 08:03:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20348 Sat 24 Mar 2018 08:02:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20386 15, age > 18 years, head Abbreviated Injury Scale [AIS] score < 3, survival for >48 hours). Demographics, ISS, physiologic parameters, SOFA and Denver scores, and outcome data were prospectively collected. Sensitivity/specificity and receiver operating characteristic curve were calculated for both scores. Analysis was also completed for a Day 3 postinjury SOFA and Denver score. Results: A total of 140 patients met the inclusion criteria (mean [SD] age, 47 [21] years; ISS, 30; male, 69%; mortality rate, 6%; mean [SD] ICU LOS, 9 [7] days; mean [SD] ventilation period, 6 [7] days). There was no difference in the score performance predicting mortality. Day 3 SOFA score of 4 or greater outperformed the Denver score of greater than 3 when predicting ICU LOS and ventilator days (area under the curve, 0.83 vs. 0.69, 0.86 vs. 0.73, respectively). The SOFA score was more sensitive and the Denver score was more specific when predicting mortality, ICU LOS, and ventilator days. Conclusion: Both scores had similar performance predicting mortality; however, the Day 3 SOFA score outperforms the Denver score when predicting ICU LOS and ventilator days. Either score could be superior based on whether one is seeking to optimize specificity or sensitivity. It is important to note that these findings are in a non–head-injured population and that there are practical difficulties using the SOFA in head-injured patients.]]> Sat 24 Mar 2018 07:58:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19855 Sat 24 Mar 2018 07:57:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19122 Sat 24 Mar 2018 07:55:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27302 Sat 24 Mar 2018 07:38:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25277 −11; odds ratio (OR) = 1.42, 95% confidence interval (CI) = 1.28–1.57). All four loci exhibited evidence for heterogeneity of effect across the stroke subtypes, with some and possibly all affecting risk for only one subtype. This suggests distinct genetic architectures for different stroke subtypes.]]> Sat 24 Mar 2018 07:38:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27385 -6) was sought in 10,617 participants of European descent, 3811 African-Americans, and 1561 young adults. Results: rs4420638, near APOE, was associated with poorer delayed recall performance in discovery (p = 5.57 x 10^-10) and replication cohorts (p = 5.65 x 10^-8). This association was stronger for paragraph than word list delayed recall and in the oldest persons. Two associations with specific tests, in subsets of the total sample, reached genome-wide significance in combined analyses of discovery and replication (rs11074779 [HS3ST4], p = 3.11 x 10^-8, and rs6813517 [SPOCK3], p = 2.58 x 10^-8) near genes involved in immune response. A genetic score combining 58 independent suggestive memory risk variants was associated with increasing Alzheimer disease pathology in 725 autopsy samples. Association of memory risk loci with gene expression in 138 human hippocampus samples showed cis-associations with WDR48 and CLDN5, both related to ubiquitin metabolism. Conclusions: This largest study to date exploring the genetics of memory function in ~40,000 older individuals revealed genome-wide associations and suggested an involvement of immune and ubiquitin pathways.]]> Sat 24 Mar 2018 07:34:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26746 70 years) living at home who initially reported taking greater than five medications. Medication review by an experienced hospital pharmacist within the ED. Rate of admission, rate of readmission, length of stay and admission to an aged care facility at 4 months post presentation, and rate of general practitioner acceptance of pharmacist recommendations. Results: The odds of admission decreased for those receiving the intervention (odds ratio [OR] = 0.68, 95% confidence interval [CI]: 0.53, 0.87; P = 0.002). There was no evidence that the intervention affected hospital length of stay for admitted patients (0.09 days change, 95% CI -0.08, 0.25; P = 0.31), the rate of re-presentation (0.08% change, 95% CI -0.12, 0.28; P = 0.44) or admission to an aged care facility. The odds of admission to an aged care facility increased with the Identification of Seniors at Risk score. General practitioners adopted 49% of pharmacists' recommendations. Conclusions: The presence of an experienced pharmacist in the ED reduced hospital admissions. Further study is required to determine longer term impacts of General Medical Practitioner acceptance of pharmacists' recommendations.]]> Sat 24 Mar 2018 07:24:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27911 −8) at 6p22.3 (rs1740828; P = 2.29 x 10⁻⁸, OR = 1.20), providing evidence of an additional region of interest for genetic susceptibility to endometrial cancer.]]> Sat 24 Mar 2018 07:24:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25211 Sat 24 Mar 2018 07:14:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23865 4 h per night during the 4-week study.]]> Sat 24 Mar 2018 07:13:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22687 Sat 24 Mar 2018 07:12:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38396 Mon 29 Jan 2024 17:47:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32690 Mon 23 Sep 2019 13:22:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32706 Mon 23 Sep 2019 11:46:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32298 Mon 23 Sep 2019 11:17:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48929 Mon 17 Apr 2023 11:14:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50984 Mon 14 Aug 2023 15:52:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50968 Mon 14 Aug 2023 15:20:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46959 Mon 12 Dec 2022 11:04:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50824 Mon 07 Aug 2023 14:29:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18788 Fri 15 May 2020 06:43:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54824 Fri 15 Mar 2024 09:11:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40026 2=0%), US$3857.34 (95% CI US$−7293.93 to US$15 008.61, I²=45.9%), US$37 577.74 (95% CI US$−649.02 to US$75 804.50, I²=92.4%) and US$14 062.42 (95% CI US$8168.69 to US$19 956.15, I²=86.4%), respectively. GLP1s were statistically significantly cost-effective compared with insulins, but not compared with DPP4i, sulfonylureas, and TZDs. Among GLP1s, liraglutide was more cost-effective compared with lixisenatide, but not compared with exenatide, with corresponding pooled INBs of US$4555.09 (95% CI US$3992.60 to US$5117.59, I²=0) and US$728.46 (95% CI US$−1436.14 to US$2893.07, I²=0), respectively. Conclusion: GLP1 agonists are a cost-effective choice compared with insulins, but not compared with DPP4i, sulfonylureas and TZDs. PROSPERO registration number: CRD42018105193.]]> Fri 15 Jul 2022 10:11:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49386 Fri 12 May 2023 14:27:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49189 Fri 05 May 2023 15:44:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24983 Fri 03 Dec 2021 10:35:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30423 Fri 03 Dec 2021 10:34:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51339 Fri 01 Sep 2023 13:35:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53516 Fri 01 Dec 2023 11:06:04 AEDT ]]>